Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Revvity, Inc. (RVTY)
USD111.85
+0.64 (+0.58%)
US NYSE S&P 500
Healthcare Medical - Diagnostics & Research
Address
77 4th Avenue 2451
Waltham, MA, US
Waltham, MA, US
CEO
Prahlad R. Singh
Website
revvity.com
IPO
1965-07-06
CIK 31791 ISIN US7140461093
Also trades on
London Stock Exchange · 0KHE.L (USD)
New York Stock Exchange · PKI (USD)
New York Stock Exchange · RVTY (USD)
Description
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
News Sentiment (7d)
Based on only 1 article — low confidence
- Revvity to Hold Earnings Call on Tuesday, August 4, 2026 Business Wire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 1985-05-09 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD111.85
+0.64 (+0.58%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.11
Float Shares
102.65M
Free Float %
91.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.35% | -0.78% | +10.59% | +3.90% | +5.49% | +2.64% | +0.81% | -14.62% | -27.97% | +82.27% | +2,900.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (29 ratings, all time)
Buy
Price Targets & DCF
Current price
111.85
Low
95.00
-15.1%
Consensus
108.88
-2.7%
Median
106.00
-5.2%
High
124.00
+10.9%
DCF (Unlevered)
118.12
+5.6%
DCF (Levered)
91.09
-18.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
44% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | -2 |
| Buy | 6 | -1 |
| Hold | 9 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 4 |
109.25
-2.3%
|
| Last Quarter | 4 |
109.25
-2.3%
|
| Last Year | 17 |
112.71
+0.8%
|
| All Time | 27 |
118.56
+6.0%
|
Quality scores
Altman Z-Score
1.81
Grey zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
7 / 10
Strong MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+3.7% Q2'26: +7.0% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%-13.7% Q2'26: +4.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+13.1% Q2'26: +13.4% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+12.6% ★ Q2'26: +10.7% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+3.3% Q2'26: +2.6% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-7.8% ★ Q2'26: -7.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×5.31× Q2'26: 4.63× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 6 EPS Ana. |
Dec 2027 8 Rev. Ana. 6 EPS Ana. |
Dec 2028 7 Rev. Ana. 1 EPS Ana. |
Dec 2029 6 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.10B
est: 2.27B (-7.4%)
|
2.12B
est: 2.26B (-6.6%)
|
2.26B
est: 2.23B (+1.0%)
|
2.78B
est: 2.77B (+0.3%)
|
2.88B
est: 2.88B (+0.1%)
|
3.78B
est: 3.65B (+3.5%)
|
3.83B
est: 4.98B (-23.1%)
|
3.31B
est: 4.59B (-27.8%)
|
2.75B
est: 2.71B (+1.6%)
|
2.76B
est: 2.75B (+0.0%)
|
2.86B
est: 2.85B (+0.3%)
|
2.86B
2.85B – 2.87B
+0.5% YoY
|
3.01B
2.98B – 3.05B
+5.1% YoY
|
3.20B
3.18B – 3.22B
+6.4% YoY
|
3.39B
3.37B – 3.42B
+5.9% YoY
|
3.59B
3.57B – 3.62B
+5.8% YoY
|
| EBITDA |
352.17M
est: 755.34M (-53.4%)
|
385.57M
est: 752.58M (-48.8%)
|
445.66M
est: 742.41M (-40.0%)
|
505.25M
est: 920.85M (-45.1%)
|
514.79M
est: 957.53M (-46.2%)
|
1.20B
est: 1.21B (-1.0%)
|
1.62B
est: 1.65B (-2.2%)
|
1.18B
est: 1.53B (-22.5%)
|
713.56M
est: 853.68M (-16.4%)
|
840.25M
est: 868.11M (-3.2%)
|
662.72M
est: 897.62M (-26.2%)
|
902.15M
899.12M – 905.18M
+0.5% YoY
|
948.44M
939.38M – 960.52M
+5.1% YoY
|
1.01B
1.00B – 1.02B
+6.4% YoY
|
1.07B
1.06B – 1.08B
+5.9% YoY
|
1.13B
1.12B – 1.14B
+5.8% YoY
|
| EBIT |
246.80M
est: 488.22M (-49.4%)
|
285.60M
est: 486.43M (-41.3%)
|
340.66M
est: 479.86M (-29.0%)
|
324.66M
est: 595.20M (-45.5%)
|
300.77M
est: 618.91M (-51.4%)
|
956.08M
est: 784.96M (+21.8%)
|
1.31B
est: 1.07B (+22.1%)
|
755.79M
est: 985.95M (-23.3%)
|
281.79M
est: 513.30M (-45.1%)
|
412.40M
est: 521.99M (-21.0%)
|
360.46M
est: 539.73M (-33.2%)
|
542.45M
540.63M – 544.27M
+0.5% YoY
|
570.29M
564.84M – 577.55M
+5.1% YoY
|
606.69M
602.83M – 610.55M
+6.4% YoY
|
642.58M
639.04M – 647.96M
+5.9% YoY
|
680.00M
676.26M – 685.70M
+5.8% YoY
|
| Net Income |
212.45M
est: 316.14M (-32.8%)
|
233.68M
est: 338.53M (-31.0%)
|
113.02M
est: 355.29M (-68.2%)
|
238.79M
est: 442.71M (-46.1%)
|
227.56M
est: 500.40M (-54.5%)
|
728.10M
est: 904.00M (-19.5%)
|
943.16M
est: 1.36B (-30.4%)
|
569.18M
est: 956.04M (-40.5%)
|
-118.38M
est: 181.20M (-165.3%)
|
295.83M
est: 546.44M (-45.9%)
|
241.68M
est: 561.42M (-57.0%)
|
595.26M
585.23M – 605.29M
+6.0% YoY
|
663.70M
641.05M – 686.36M
+11.5% YoY
|
734.13M
727.52M – 740.75M
+10.6% YoY
|
802.01M
796.27M – 810.75M
+9.2% YoY
|
884.58M
878.25M – 894.22M
+10.3% YoY
|
| SGA |
551.20M
est: 518.71M (+6.3%)
|
542.80M
est: 516.81M (+5.0%)
|
585.56M
est: 509.83M (+14.9%)
|
694.17M
est: 632.36M (+9.8%)
|
698.24M
est: 657.56M (+6.2%)
|
765.33M
est: 833.98M (-8.2%)
|
741.61M
est: 1.14B (-34.7%)
|
757.99M
est: 1.05B (-27.6%)
|
706.12M
est: 687.86M (+2.7%)
|
715.30M
est: 699.50M (+2.3%)
|
945.29M
est: 723.27M (+30.7%)
|
726.92M
724.48M – 729.36M
+0.5% YoY
|
764.22M
756.92M – 773.96M
+5.1% YoY
|
813.01M
807.83M – 818.18M
+6.4% YoY
|
861.10M
856.36M – 868.31M
+5.9% YoY
|
911.24M
906.23M – 918.88M
+5.8% YoY
|
| EPS |
1.89
est: 2.57 (-26.6%)
|
2.13
est: 2.76 (-22.6%)
|
1.03
est: 2.89 (-64.4%)
|
2.16
est: 3.60 (-40.1%)
|
2.05
est: 4.07 (-49.6%)
|
6.53
est: 7.36 (-11.3%)
|
8.12
est: 11.04 (-26.4%)
|
4.51
est: 7.78 (-42.0%)
|
-0.95
est: 1.60 (-159.4%)
|
2.41
est: 4.85 (-50.3%)
|
2.08
est: 4.94 (-57.9%)
|
5.29
5.17 – 5.35
+7.1% YoY
|
5.85
5.66 – 6.06
+10.6% YoY
|
6.47
6.43 – 6.54
+10.7% YoY
|
7.08
7.03 – 7.16
+9.4% YoY
|
7.81
7.76 – 7.90
+10.3% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-07 | Barclays | Equal Weight | Equal Weight | Maintain |
| 2026-05-06 | TD Cowen | Buy | Buy | Maintain |
| 2026-05-04 | Baird | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
530.71M
OE per share TTM
4.61
Owner's Yield
4.78%
Maintenance CapEx ratio
26.27%
Maint CapEx / Avg PPE
19.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
1
Beneficial owners (>5%)
2
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 52-0556948 | 6.48M | 5.30% | 6.42M | — | 6.48M | — | IA | Maryland | 2024-11-14 | ↗ |
| 2 | EIN #00-0000000 | 6.34M | 5.10% | — | 6.34M | — | 6.34M | IA, HC | Jersey, Channel Islands | 2024-11-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 110 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | T. Rowe Price Capital Appreciation Equity ETF TCAF | 1.48% | 113.48M | 0.31% |
| 2 | Pacer Lunt Large Cap Alternator ETF ALTL | 0.91% | 898.6K | 0.60% |
| 3 | First Trust Health Care AlphaDEX Fund FXH | 0.44% | 4.36M | 0.61% |
| 4 | Dimensional - US Small Cap Value ETF DFSV | 0.44% | 34.74M | 0.30% |
| 5 | T. Rowe Price Small-Mid Cap ETF TMSL | 0.35% | 9.65M | 0.55% |
| 6 | Dimensional - US Targeted Value ETF DFAT | 0.35% | 49.33M | 0.28% |
| 7 | Vanguard Small-Cap Value ETF VBR | 0.26% | 172.27M | 0.05% |
| 8 | WisdomTree U.S. MidCap Fund EZM | 0.24% | 2.23M | 0.38% |
| 9 | Schwab U.S. Mid-Cap ETF SCHM | 0.23% | 34.24M | 0.03% |
| 10 | State Street Health Care Select Sector SPDR ETF XLV | 0.22% | 89.42M | 0.08% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
80.00
Cash buys
—
Cash sales
1.00
Net activity
-80
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-20 | Gonzales Anita | Officer | S-Sale | D | Common Stock | 80 | 92.80 | 7.4K | 7,319 | D | ↗ |
| 2026-03-16 | Gonzales Anita | Officer | A-Award | A | Common Stock | 1,600 | 0.00 | — | 7,399 | D | ↗ |
| 2026-03-06 | Gonzales Anita | Officer | A-Award | A | Common Stock | 1,721 | 0.00 | — | 5,799 | D | ↗ |
| 2026-02-24 | Victor Miriame | Officer | M-Exempt | A | Common Stock | 1,862 | 95.74 | 178.3K | 19,984 | D | ↗ |
| 2026-02-23 | McMurry-Heath Michelle | Director | S-Sale | D | Common Stock | 600 | 97.26 | 58.4K | 4,233 | D | ↗ |
| 2026-02-17 | Vohra Tajinder S | Officer | F-InKind | D | Common Stock | 566 | 96.03 | 54.4K | 13,965 | D | ↗ |
| 2026-02-17 | Victor Miriame | Officer | F-InKind | D | Common Stock | 1,031 | 96.03 | 99.0K | 18,122 | D | ↗ |
| 2026-02-17 | Singh Prahlad R. | Director / Officer | F-InKind | D | Common Stock | 6,901 | 96.03 | 662.7K | 113,312 | D | ↗ |
| 2026-02-17 | Krakowiak Maxwell | Officer | F-InKind | D | Common Stock | 902 | 96.03 | 86.6K | 16,412 | D | ↗ |
| 2026-02-17 | Gonzales Anita | Officer | F-InKind | D | Common Stock | 85 | 96.03 | 8.2K | 4,078 | D | ↗ |
| 2026-02-17 | Goldberg Joel S | Officer | F-InKind | D | Common Stock | 1,733 | 96.03 | 166.4K | 41,514 | D | ↗ |
| 2026-02-05 | Singh Prahlad R. | Director / Officer | S-Sale | D | Common Stock | 1,068 | 102.52 | 109.5K | 120,213 | D | ↗ |
| 2026-02-05 | Goldberg Joel S | Officer | M-Exempt | D | NQ Stock Option (right to buy) | 12,717 | 92.09 | 1.17M | 0 | D | ↗ |
| 2026-02-04 | Vohra Tajinder S | Officer | A-Award | A | Common Stock | 4,448 | 0.00 | — | 14,531 | D | ↗ |
| 2026-02-04 | Victor Miriame | Officer | F-InKind | D | Common Stock | 536 | 101.13 | 54.2K | 13,752 | D | ↗ |
| 2026-02-04 | Singh Prahlad R. | Director / Officer | A-Award | A | Common Stock | 26,796 | 0.00 | — | 120,213 | D | ↗ |
| 2026-02-04 | Krakowiak Maxwell | Officer | F-InKind | D | Common Stock | 708 | 101.13 | 71.6K | 11,509 | D | ↗ |
| 2026-02-04 | Goldberg Joel S | Officer | A-Award | A | NQ Stock Option (right to buy) | 18,383 | 103.40 | 1.90M | 18,383 | D | ↗ |
| 2026-02-02 | Vohra Tajinder S | Officer | M-Exempt | A | NQ Stock Option (right to buy) | 5,756 | 92.09 | 530.1K | 0 | D | ↗ |
| 2025-12-15 | Gonzales Anita | Officer | F-InKind | D | Common Stock | 25 | 100.49 | 2.5K | 4,315 | D | ↗ |
| 2025-10-29 | Singh Prahlad R. | Director / Officer | G-Gift | A | Common Stock | 9,420 | 0.00 | — | 46,583 | I | ↗ |
| 2025-09-15 | Krakowiak Maxwell | Officer | F-InKind | D | Common Stock | 559 | 82.87 | 46.3K | 12,217 | D | ↗ |
| 2025-09-15 | Gonzales Anita | Officer | F-InKind | D | Common Stock | 149 | 82.87 | 12.3K | 4,340 | D | ↗ |
| 2025-08-27 | MICHAS ALEXIS P | Director | S-Sale | D | Common Stock | 500 | 89.01 | 44.5K | 7,270 | I | ↗ |
| 2025-08-15 | Vohra Tajinder S | Officer | G-Gift | A | Common Stock | 12,183 | 0.00 | — | 12,183 | I | ↗ |
| 2025-08-15 | Victor Miriame | Officer | A-Award | A | NQ Stock Option (right to buy) | 32,382 | 90.47 | 2.93M | 32,382 | D | ↗ |
| 2025-08-15 | Krakowiak Maxwell | Officer | A-Award | A | NQ Stock Option (right to buy) | 44,446 | 90.47 | 4.02M | 44,446 | D | ↗ |
| 2025-06-16 | Gonzales Anita | Officer | F-InKind | D | Common Stock | 33 | 93.53 | 3.1K | 4,489 | D | ↗ |
| 2025-05-29 | McMurry-Heath Michelle | Director | S-Sale | D | Common Stock | 600 | 92.17 | 55.3K | 4,833 | D | ↗ |
| 2025-04-30 | Witz Pascale | Director | A-Award | A | Common Stock | 1,338 | 0.00 | — | 13,705 | D | ↗ |
| 2025-04-30 | Witney Frank | Director | A-Award | A | Common Stock | 1,074 | 0.00 | — | 19,736 | D | ↗ |
| 2025-04-30 | Vounatsos Michel | Director | A-Award | A | Common Stock | 1,074 | 0.00 | — | 10,359 | D | ↗ |
| 2025-04-30 | Vandebroek Sophie V. | Director | A-Award | A | Common Stock | 1,338 | 0.00 | — | 5,088 | D | ↗ |
| 2025-04-30 | McMurry-Heath Michelle | Director | A-Award | A | Common Stock | 1,074 | 0.00 | — | 4,095 | D | ↗ |
| 2025-04-30 | MICHAS ALEXIS P | Director | A-Award | A | Common Stock | 1,288 | 0.00 | — | 59,502 | D | ↗ |
| 2025-04-30 | Klobuchar Michael A | Director | A-Award | A | Common Stock | 1,338 | 0.00 | — | 5,088 | D | ↗ |
| 2025-04-30 | Chapin Samuel R. | Director | A-Award | A | Common Stock | 1,338 | 0.00 | — | 20,396 | D | ↗ |
| 2025-04-30 | Barrett Peter | Director | A-Award | A | Common Stock | 1,338 | 0.00 | — | 26,013 | D | ↗ |
| 2025-03-21 | Gonzales Anita | Officer | A-Award | A | Common Stock | 732 | 0.00 | — | 4,522 | D | ↗ |
| 2025-02-18 | Krakowiak Maxwell | Officer | F-InKind | D | Common Stock | 50 | 112.26 | 5.6K | 12,776 | D | ↗ |
| 2025-02-18 | Gonzales Anita | Officer | F-InKind | D | Common Stock | 69 | 112.26 | 7.7K | 3,873 | D | ↗ |
| 2025-02-06 | McMurry-Heath Michelle | Director | S-Sale | D | Common Stock | 1,970 | 119.49 | 235.4K | 3,021 | D | ↗ |
| 2025-02-04 | Vohra Tajinder S | Officer | A-Award | A | NQ Stock Option (right to buy) | 9,069 | 123.35 | 1.12M | 9,069 | D | ↗ |
| 2025-02-04 | Victor Miriame | Officer | F-InKind | D | Common Stock | 342 | 123.69 | 42.3K | 10,128 | D | ↗ |
| 2025-02-04 | Singh Prahlad R. | Director / Officer | A-Award | A | Common Stock | 20,920 | 0.00 | — | 106,258 | D | ↗ |
| 2025-02-04 | Krakowiak Maxwell | Officer | A-Award | A | NQ Stock Option (right to buy) | 15,784 | 123.35 | 1.95M | 15,784 | D | ↗ |
| 2025-02-04 | Goldberg Joel S | Officer | A-Award | A | NQ Stock Option (right to buy) | 13,656 | 123.35 | 1.68M | 13,656 | D | ↗ |
| 2025-01-30 | Goldberg Joel S | Officer | M-Exempt | A | Common Stock | 15,170 | 81.29 | 1.23M | 48,570 | D | ↗ |
| 2025-01-07 | Vohra Tajinder S | Officer | M-Exempt | A | Common Stock | 5,492 | 81.29 | 446.4K | 25,144 | D | ↗ |
| 2024-12-16 | Gonzales Anita | Officer | F-InKind | D | Common Stock | 25 | 115.94 | 2.9K | 3,992 | D | ↗ |
| 2024-12-02 | Singh Prahlad R. | Director / Officer | S-Sale | D | Common Stock | 3,277 | 116.63 | 382.2K | 90,195 | D | ↗ |
| 2024-10-09 | Vohra Tajinder S | Officer | S-Sale | D | Common Stock | 2,134 | 121.72 | 259.8K | 19,672 | D | ↗ |
| 2024-10-08 | Vohra Tajinder S | Officer | S-Sale | D | Common Stock | 1,661 | 122.47 | 203.4K | 22,299 | D | ↗ |
| 2024-10-07 | Vohra Tajinder S | Officer | S-Sale | D | Common Stock | 2,053 | 122.04 | 250.5K | 24,060 | D | ↗ |
| 2024-09-16 | Gonzales Anita | Officer | F-InKind | D | Common Stock | 149 | 122.03 | 18.2K | 4,017 | — | ↗ |
| 2024-08-15 | MICHAS ALEXIS P | Director | S-Sale | D | Common Stock | 850 | 118.62 | 100.8K | 7,770 | — | ↗ |
| 2024-08-07 | Goldberg Joel S | Officer | S-Sale | D | Common Stock | 785 | 118.80 | 93.3K | 34,448 | — | ↗ |
| 2024-06-17 | Gonzales Anita | Officer | F-InKind | D | Common Stock | 32 | 108.65 | 3.5K | 4,166 | — | ↗ |
| 2024-06-07 | Goldberg Joel S | Officer | S-Sale | D | Common Stock | 2,824 | 110.32 | 311.5K | 38,076 | — | ↗ |
| 2024-05-01 | Witz Pascale | Director | A-Award | A | Common Stock | 977 | 0.00 | — | 10,075 | — | ↗ |
| 2024-05-01 | Witney Frank | Director | A-Award | A | Common Stock | 1,218 | 0.00 | — | 18,662 | — | ↗ |
| 2024-05-01 | Vounatsos Michel | Director | A-Award | A | Common Stock | 977 | 0.00 | — | 8,067 | — | ↗ |
| 2024-05-01 | Vandebroek Sophie V. | Director | A-Award | A | Common Stock | 977 | 0.00 | — | 1,458 | — | ↗ |
| 2024-05-01 | McMurry-Heath Michelle | Director | A-Award | A | Common Stock | 977 | 0.00 | — | 3,773 | — | ↗ |
| 2024-05-01 | MICHAS ALEXIS P | Director | A-Award | A | Common Stock | 1,173 | 0.00 | — | 56,777 | — | ↗ |
| 2024-05-01 | Klobuchar Michael A | Director | A-Award | A | Common Stock | 977 | 0.00 | — | 1,458 | — | ↗ |
| 2024-05-01 | Chapin Samuel R. | Director | A-Award | A | Common Stock | 1,218 | 0.00 | — | 17,984 | — | ↗ |
| 2024-05-01 | Barrett Peter | Director | A-Award | A | Common Stock | 977 | 0.00 | — | 22,383 | — | ↗ |
| 2024-04-15 | Gonzales Anita | Officer | F-InKind | D | Common Stock | 108 | 103.49 | 11.2K | 4,198 | — | ↗ |
| 2024-03-26 | Singh Prahlad R. | Director / Officer | G-Gift | A | Common Stock | 12,075 | 0.00 | — | 37,163 | — | ↗ |
| 2024-03-01 | Gonzales Anita | Officer | A-Award | A | NQ Stock Option (right to buy) | 1,978 | 107.48 | 212.6K | 1,978 | — | ↗ |
| 2024-02-29 | MICHAS ALEXIS P | Director | S-Sale | D | Common Stock | 5,000 | 109.98 | 549.9K | 55,604 | — | ↗ |
| 2024-02-27 | Vohra Tajinder S | Officer | M-Exempt | A | Common Stock | 7,918 | 54.57 | 432.0K | 34,031 | — | ↗ |
| 2024-02-23 | Singh Prahlad R. | Director / Officer | S-Sale | D | Common Stock | 1,144 | 105.13 | 120.3K | 102,270 | — | ↗ |
| 2024-02-23 | Goldberg Joel S | Officer | S-Sale | D | Common Stock | 835 | 105.13 | 87.8K | 40,900 | — | ↗ |
| 2024-02-15 | Vandebroek Sophie V. | Director | A-Award | A | Common Stock | 264 | 0.00 | — | 481 | — | ↗ |
| 2024-02-15 | Krakowiak Maxwell | Officer | F-InKind | D | Common Stock | 50 | 103.56 | 5.2K | 7,117 | — | ↗ |
| 2024-02-15 | Klobuchar Michael A | Director | A-Award | A | Common Stock | 264 | 0.00 | — | 481 | — | ↗ |
| 2024-02-15 | Gonzales Anita | Officer | F-InKind | D | Common Stock | 69 | 103.56 | 7.1K | 3,591 | — | ↗ |
| 2024-02-05 | Vohra Tajinder S | Officer | M-Exempt | A | Common Stock | 3,554 | 105.62 | 375.4K | 27,359 | — | ↗ |
| 2024-02-05 | Victor Miriame | Officer | F-InKind | D | Common Stock | 258 | 105.62 | 27.2K | 10,470 | — | ↗ |
| 2024-02-05 | Tereau Daniel R | Officer | M-Exempt | A | Common Stock | 2,835 | 105.62 | 299.4K | 14,446 | — | ↗ |
| 2024-02-05 | Singh Prahlad R. | Director / Officer | S-Sale | D | Common Stock | 6,468 | 104.80 | 677.8K | 92,801 | — | ↗ |
| 2024-02-05 | Krakowiak Maxwell | Officer | A-Award | A | NQ Stock Option (right to buy) | 28,028 | 104.64 | 2.93M | 28,028 | — | ↗ |
| 2024-02-05 | Goldberg Joel S | Officer | S-Sale | D | Common Stock | 3,662 | 104.80 | 383.8K | 38,292 | — | ↗ |
| 2024-02-01 | Vandebroek Sophie V. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-01 | Klobuchar Michael A | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-09-15 | Gonzales Anita | Officer | F-InKind | D | Common Stock | 149 | 112.71 | 16.8K | 3,710 | — | ↗ |
Executive team
Top executives
EBIT / Employee
32.8K
Shares Outstanding
111.80M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Prahlad R. Singh | Chief Executive Officer, President & Director | 4M | — |
| Joel S. Goldberg | Senior Vice President of Administration, General Counsel & Secretary | 1M | male |
| Maxwell Krakowiak | Senior Vice President & Chief Financial Officer | 1M | male |
| Miriame Victor | Senior Vice President & Chief Commercial Officer | 1M | female |
| Tajinder Vohra | Senior Vice President of Global Operations | 1M | male |
| Magali Four | Senior Vice President & Chief People and Culture Officer | — | female |
| Madhuri FACMG | Senior Vice President & Chief Scientific Officer | — | female |
| Bryan A. Kipp | Senior Vice President of Technology & Licensing | — | male |
| Stephen Barr Willoughby | Senior Vice President of Investor Relations & Head of ESG | — | male |
| Anita Gonzales | Chief Accounting Officer, Vice President & Controller | — | female |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-09-29 | 2025-10-03 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-09-12 | 2025-10-10 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-08-26 | 2025-09-12 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-08-26 | 2025-09-12 | Ro Khanna | CA17 | — | Sale | $1,000 - $15,000 | ↗ |
| 2025-08-13 | 2025-09-12 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-07-23 | 2025-08-15 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-07-22 | 2025-08-13 | Lisa McClain | MI09 | Spouse | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2025-06-17 | 2025-08-13 | Lisa McClain | MI09 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2025-06-11 | 2025-07-11 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-05-28 | 2025-06-06 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-05-28 | 2025-06-09 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-08 | 2025-05-08 | Rob Bresnahan | PA08 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-02-28 | 2025-03-21 | John Delaney | MD06 | — | Sale | $15,001 - $50,000 | ↗ |
| 2025-02-25 | 2025-03-28 | Rob Bresnahan | PA08 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-11-15 | 2024-12-06 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-10-31 | 2023-11-08 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2023-10-02 | 2023-11-08 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-06-26 | 2023-07-11 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2023-05-23 | 2023-06-12 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-03-14 | 2023-04-07 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RVTY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
